NO20063026L - Antistoffer - Google Patents
AntistofferInfo
- Publication number
- NO20063026L NO20063026L NO20063026A NO20063026A NO20063026L NO 20063026 L NO20063026 L NO 20063026L NO 20063026 A NO20063026 A NO 20063026A NO 20063026 A NO20063026 A NO 20063026A NO 20063026 L NO20063026 L NO 20063026L
- Authority
- NO
- Norway
- Prior art keywords
- binds
- amino acid
- acid sequence
- fragment
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52517403P | 2003-11-28 | 2003-11-28 | |
PCT/EP2004/013426 WO2005051998A2 (en) | 2003-11-28 | 2004-11-26 | Antibodies binding to a c-terminal fragment of apolipoprotein e |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20063026L true NO20063026L (no) | 2006-08-28 |
Family
ID=33564077
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20063026A NO20063026L (no) | 2003-11-28 | 2006-06-28 | Antistoffer |
Country Status (16)
Country | Link |
---|---|
US (1) | US8058016B2 (ja) |
EP (2) | EP2343318A3 (ja) |
JP (1) | JP4869074B2 (ja) |
KR (2) | KR20120108061A (ja) |
CN (1) | CN1890266B (ja) |
AR (1) | AR047729A1 (ja) |
AU (1) | AU2004293180B2 (ja) |
BR (1) | BRPI0417023A (ja) |
CA (1) | CA2547675A1 (ja) |
GB (1) | GB2408508A (ja) |
IL (1) | IL175608A0 (ja) |
NO (1) | NO20063026L (ja) |
RU (1) | RU2006122946A (ja) |
TW (1) | TW200530267A (ja) |
UY (1) | UY28641A1 (ja) |
WO (1) | WO2005051998A2 (ja) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
US7691965B2 (en) | 2002-05-08 | 2010-04-06 | The Regents Of The University Of California | Helical synthetic peptides that stimulate cellular cholesterol efflux |
JP5401001B2 (ja) | 2002-09-11 | 2014-01-29 | ジェネンテック, インコーポレイテッド | 免疫関連疾患の治療のための新規組成物と方法 |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
GB0621513D0 (en) * | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
AU2008204335B2 (en) * | 2007-01-11 | 2013-06-13 | Michael Bacher | Diagnosis and treatment of Alzheimer's and other neurodementing diseases |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
CN101668771B (zh) | 2007-03-12 | 2013-08-21 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 单链抗体的基于序列的工程改造和最优化 |
KR101530723B1 (ko) | 2007-06-25 | 2015-06-22 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 단일 쇄 항체의 서열에 기초한 공학처리 및 최적화 |
SI2158315T1 (sl) * | 2007-06-25 | 2016-05-31 | Esbatech, An Alcon Biomedical Research Unit Llc | Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi |
EP2193144A4 (en) | 2007-09-05 | 2012-06-27 | Nurit Rachamim | ANTIBODIES TO FLAGELLIN AND APPLICATIONS THEREOF |
JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
KR101855381B1 (ko) | 2008-04-09 | 2018-05-09 | 제넨테크, 인크. | 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법 |
EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
JP2014502276A (ja) * | 2010-12-02 | 2014-01-30 | ワシントン・ユニバーシティ | アミロイドプラーク関連症状の治療のための組成物及び方法 |
CN102863525B (zh) * | 2011-07-04 | 2014-06-04 | 武汉大学 | 一种重组人apoE拟肽及制备方法和应用 |
TWI685349B (zh) | 2013-07-16 | 2020-02-21 | 建南德克公司 | 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法 |
ES2924071T3 (es) | 2015-09-02 | 2022-10-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT) |
BR112018005862A2 (pt) | 2015-09-25 | 2018-10-16 | Genentech, Inc. | anticorpos, anticorpos isolados, polinucleotídeo, vetor, célula hospedeira, método de produção do anticorpo, imunoconjugado, composição, usos dos anticorpos, métodos para tratar ou retardar a progressão de um câncer e de uma doença e para aumentar, potencializar ou estimular uma resposta ou função imune e kit |
JP2019500893A (ja) * | 2015-11-03 | 2019-01-17 | ヤンセン バイオテツク,インコーポレーテツド | Pd−1及びtim−3に特異的に結合する抗体及びそれらの使用 |
EP3532034A4 (en) * | 2016-10-28 | 2020-12-02 | Washington University | ANTI-APOE ANTIBODIES |
EP3597222A1 (en) * | 2018-07-16 | 2020-01-22 | Easemedcontrol R & D GmbH & Co KG | Treatment and diagnosis of unresolved inflammatory diseases |
WO2020176871A1 (en) * | 2019-02-28 | 2020-09-03 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Kawasaki disease antibodies identify hepacivirus peptides |
EP3757121A1 (en) * | 2019-06-28 | 2020-12-30 | Eisai R&D Management Co., Ltd. | Apolipoprotein e fragments |
KR20220160640A (ko) * | 2020-03-27 | 2022-12-06 | 에피백스, 인크. | 조절 t-세포 에피토프 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2148116T1 (es) * | 1992-10-13 | 2000-10-16 | Univ Duke | Metodos de detectar la enfermedad de alzheimer. |
US6107045A (en) | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
US6046381A (en) | 1998-04-30 | 2000-04-04 | The Regents Of The University Of California | Apolipoprotein E transgenic mice and assay methods |
EP1133699A1 (en) * | 1998-11-25 | 2001-09-19 | Scios Inc. | Prevention and treatment of amyloid-associated disorders |
CA2426030C (en) * | 2000-11-03 | 2013-12-31 | The J. David Gladstone Institutes | Methods of treating disorders related to apoe |
AU2002222308A1 (en) * | 2000-12-29 | 2002-07-16 | Oxford Glycosciences (Uk) Ltd. | Proteins, genes and their use for diagnosis and treatment of vascular response |
DE60225821T2 (de) * | 2001-10-04 | 2009-04-30 | Immuno-Biological Laboratories Co., Ltd., Takasaki | Reagens zum Nachweis eines Risikofaktors der Alzheimer-Krankheit, Nachweiskit dafür und Verfahren zum Nachweis eines Risikofaktors der Alzheimer-Krankheit unter ihrer Verwendung |
EP1543331B1 (en) | 2002-07-30 | 2009-02-11 | The J. David Gladstone Institutes | Method of diagnosing alzheimer's disease |
-
2004
- 2004-11-26 WO PCT/EP2004/013426 patent/WO2005051998A2/en active Application Filing
- 2004-11-26 AR ARP040104408A patent/AR047729A1/es unknown
- 2004-11-26 UY UY28641A patent/UY28641A1/es unknown
- 2004-11-26 EP EP10195280A patent/EP2343318A3/en not_active Withdrawn
- 2004-11-26 EP EP04819225A patent/EP1687336A2/en not_active Withdrawn
- 2004-11-26 KR KR1020127023844A patent/KR20120108061A/ko not_active Application Discontinuation
- 2004-11-26 AU AU2004293180A patent/AU2004293180B2/en not_active Ceased
- 2004-11-26 BR BRPI0417023-7A patent/BRPI0417023A/pt not_active IP Right Cessation
- 2004-11-26 CN CN2004800352575A patent/CN1890266B/zh not_active Expired - Fee Related
- 2004-11-26 RU RU2006122946/13A patent/RU2006122946A/ru not_active Application Discontinuation
- 2004-11-26 JP JP2006540392A patent/JP4869074B2/ja not_active Expired - Fee Related
- 2004-11-26 GB GB0426043A patent/GB2408508A/en not_active Withdrawn
- 2004-11-26 CA CA002547675A patent/CA2547675A1/en not_active Abandoned
- 2004-11-26 KR KR1020067010370A patent/KR20060120161A/ko active Application Filing
- 2004-11-29 TW TW093136755A patent/TW200530267A/zh unknown
-
2006
- 2006-05-11 IL IL175608A patent/IL175608A0/en unknown
- 2006-06-28 NO NO20063026A patent/NO20063026L/no not_active Application Discontinuation
-
2009
- 2009-09-08 US US12/585,180 patent/US8058016B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TW200530267A (en) | 2005-09-16 |
AU2004293180A1 (en) | 2005-06-09 |
CN1890266B (zh) | 2012-10-03 |
AR047729A1 (es) | 2006-02-15 |
IL175608A0 (en) | 2006-09-05 |
AU2004293180B2 (en) | 2011-09-15 |
EP2343318A3 (en) | 2013-02-27 |
WO2005051998A3 (en) | 2007-07-26 |
CN1890266A (zh) | 2007-01-03 |
KR20060120161A (ko) | 2006-11-24 |
UY28641A1 (es) | 2005-06-30 |
US8058016B2 (en) | 2011-11-15 |
WO2005051998A2 (en) | 2005-06-09 |
GB2408508A (en) | 2005-06-01 |
US20100061993A1 (en) | 2010-03-11 |
KR20120108061A (ko) | 2012-10-04 |
CA2547675A1 (en) | 2005-06-09 |
EP2343318A2 (en) | 2011-07-13 |
BRPI0417023A (pt) | 2007-02-21 |
JP4869074B2 (ja) | 2012-02-01 |
RU2006122946A (ru) | 2008-01-10 |
JP2008502311A (ja) | 2008-01-31 |
GB0426043D0 (en) | 2004-12-29 |
EP1687336A2 (en) | 2006-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063026L (no) | Antistoffer | |
CY1118037T1 (el) | Αντισωματα εναντι του αβητα και h χρηση τους | |
ATE496063T1 (de) | Hybrid und tandemproteine von neisseria sp | |
CY1118443T1 (el) | Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
RS54133B1 (en) | ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES | |
AR047347A1 (es) | Miembros de la familia cry9 de bacillus | |
WO2005087811A3 (en) | Estrogen receptors and methods of use | |
EA200700136A1 (ru) | Анти-cd154-антитела | |
PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
ATE368688T1 (de) | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen | |
ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
ATE466874T1 (de) | Mit scytovirin der domäne 1 verwandte polypeptide | |
ATE466876T1 (de) | Immunogene konstrukte | |
ATE543906T1 (de) | Antigen von streptococcus aus der b-gruppe | |
DK1368372T3 (da) | Peptid med affinitet til det virale gp120-protein samt anvendelse deraf | |
EA200901441A1 (ru) | Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90 | |
ATE387629T1 (de) | Gemeinsame epitope von antigenen aus einer multigen-familie | |
DK1117682T3 (da) | Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere | |
CY1111630T1 (el) | Παραγωγα κυτοκινων | |
ATE441865T1 (de) | Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila | |
ATE342978T1 (de) | Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c | |
DE602006017806D1 (de) | Behandlung von neurodegeneration | |
NO20082864L (no) | Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav | |
NO20082810L (no) | Vaksine, og anvendelse av samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |